Palantir Technologies Inc. is trading 3.7% down at $131.47 following reports that the UK government is reviewing its £330 million NHS data platform contract.
- UK lawmakers are reportedly urging ministers to exercise a 2027 break clause to terminate the agreement, creating uncertainty around the high-profile deal.
- The stock is facing additional macro pressure as the broader technology sector underperforms major U.S. indices.
- Investors remain sensitive to headline risks involving the company's government partnerships and its long-term AI-driven growth narrative.